Literature DB >> 6135764

The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy.

M Nakajo, B Shapiro, J Copp, V Kalff, M D Gross, J C Sisson, W H Beierwaltes.   

Abstract

The scintigraphic distribution of m-[131I]iodobenzylguanidine (I-131 MIBG), an adrenal medullary imaging agent, was studied to determine the patterns of uptake of this agent in man. The normal distribution of I-131 MIBG includes clear portrayal of the salivary glands, liver, spleen, and urinary bladder. The heart, middle and lower lung zones, and colon were less frequently or less clearly seen. The upper lung zones and kidneys were seldom visualized. The thyroid appeared only in cases of inadequate thyroidal blockade. The "normal" adrenal glands were seldom seen and faintly imaged in 2% at 24 hr after injection and in 16% at 48 hr, in patients shown not to have pheochromocytomas, whereas intra-adrenal, extraadrenal, and malignant pheochromocytomas usually appeared as intense focal areas of I-131 MIBG uptake at 24 through 72 hr.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135764

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  47 in total

1.  Guidelines for radioiodinated MIBG scintigraphy in children.

Authors:  Pierre Olivier; Paula Colarinha; Jure Fettich; Sibylle Fischer; Jörgen Frökier; Francesco Giammarile; Isky Gordon; Klaus Hahn; Levent Kabasakal; Mike Mann; Mercedes Mitjavila; Amy Piepsz; Ute Porn; Rune Sixt; Jeannette van Velzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-26       Impact factor: 9.236

2.  131I/123I-metaiodobenzylguanidine (MIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

3.  131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Francesco Giammarile; Cumali Aktolun; Richard P Baum; Angelika Bischof Delaloye; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Giovanna Pepe; Sven N Reske; Maria R Castellani; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

4.  Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine.

Authors:  F A Khafagi; B Shapiro; M Fischer; J C Sisson; R Hutchinson; W H Beierwaltes
Journal:  Eur J Nucl Med       Date:  1991

5.  Plasma gut hormone levels in 37 patients with pheochromocytomas.

Authors:  A I Vinik; B Shapiro; N W Thompson
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

Review 6.  Radiopharmaceutical diagnosis and therapy of sympatho-medullary disorders.

Authors:  B Shapiro
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

7.  Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.

Authors:  Y Nakabeppu; M Nakajo
Journal:  Ann Nucl Med       Date:  1994-11       Impact factor: 2.668

8.  The usefulness of cardio-vascular visualization in the localization of mediastinal pheochromocytomas with I-131-MIBG.

Authors:  T Başoğlu; P Olivier; T Arsena; P Y Marie; J L Schlienger; G Karcher; A Bertrand
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

Review 9.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03

10.  False-positive diagnosis of adrenal pheochromocytoma on iodine-123-MIBG scan.

Authors:  C Letizia; G De Toma; R Massa; A Corsi; C Caliumi; S Subioli; E D'Erasmo
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.